Radius Health receives FDA Fast Track designation for elacestrant (RAD1901)
Radius Health announced the FDA has granted Fast Track designation for elacestrant, an investigational oral selective estrogen receptor down-regulator/degrader as a treatment of women with ER+ and HER2- advanced or metastatic breast cancer. October 18, 2017